Shares of Evotec AG (NASDAQ:EVTCY) have been given an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.

Zacks has also assigned Evotec AG an industry rank of 168 out of 265 based on the ratings given to related companies.

EVTCY has been the subject of a number of recent research reports. DZ Bank AG reaffirmed a “sell” rating on shares of Evotec AG in a research report on Monday, July 31st. Zacks Investment Research downgraded Evotec AG from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Evotec AG (EVTCY) to Post $0.12 Earnings Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at

Evotec AG (NASDAQ EVTCY) traded up 6.8016% during mid-day trading on Friday, hitting $40.9584. 18,629 shares of the company traded hands. The company has a market capitalization of $3.00 billion and a price-to-earnings ratio of 68.7221. Evotec AG has a one year low of $10.86 and a one year high of $52.82. The company’s 50-day moving average price is $46.42 and its 200 day moving average price is $33.89.

Evotec AG (NASDAQ:EVTCY) last issued its quarterly earnings data on Thursday, August 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). The company had revenue of $58.52 million during the quarter, compared to analyst estimates of $50.06 million.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with's FREE daily email newsletter.